Cytomegalovirus infection in pediatric patients with hepatoblastoma after liver transplantation. (26th July 2018)

• Record Type: Journal Article
• Authors: Nodomi, Seishiro; Umeda, Katsutsugu; Kato, Itaru; Saida, Satoshi; Hiramatsu, Hidefumi; Ogawa, Eri; Yoshizawa, Atsushi; Okamoto, Shinya; Okajima, Hideaki; Uemoto, Shinji; Adachi, Souichi
• Is Part Of: Pediatric transplantation. Volume 22:Number 7(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-07-26
• Subjects: cytomegalovirus -- hepatoblastoma -- liver transplantation -- pediatric -- preemptive antiviral therapy; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.13273
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: No studies have examined CMV infection in pediatric patients with HB receiving LT. Here, we retrospectively analyzed the incidence of and risk factors for CMV infection in 24 pediatric patients with HB who underwent LT between 1997 and 2015. CMV infection was monitored by measuring expression of pp65 CMV antigen for up to 4 months post‐LT. CMV infection, defined as detection of at least one pp65‐positive leukocyte, was detected in nine (37.5%) patients who did not develop CMV disease. Nine (47.4%) of nineteen patients who received post‐LT chemotherapy experienced CMV infection; however, no CMV infection was observed in the five patients who did not receive post‐LT chemotherapy ( P = 0.012). There were no significant differences in the incidence of CMV infection between patients with ACR (60.0%) and those without (21.4%, P = 0.092), or between CMV seropositive (55.6%) and seronegative patients (33.3%, P = 0.675). All nine patients with CMV infection did not experience CMV disease due to the use of preemptive antiviral therapy. Close monitoring of CMV infection is recommended for patients with HB, particularly those receiving post‐LT chemotherapy. Preemptive antiviral therapy is feasible for prophylaxis of CMV disease.